Enanta Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q with the SEC on August 12, 2026, covering the three- and nine-month periods ended June 30, 2026.

Key Highlights

  • Royalty revenue: Total revenue for the three months ended June 30, 2026 was $14,359 thousand, compared with $18,314 thousand in the same prior-year period, according to the filing.
  • Net loss: The company reported a net loss of $19,501 thousand for the three months ended June 30, 2026, versus a net loss of $18,255 thousand in the year-earlier quarter.
  • Nine-month net loss: For the nine months ended June 30, 2026, the net loss was $44,530 thousand, compared with $63,189 thousand in the nine months ended June 30, 2025.
  • Shares outstanding: As of August 7, 2026, the registrant had 29,125,402 shares of common stock outstanding.
  • Total assets: Total assets were $296,870 thousand at June 30, 2026, up from $280,732 thousand at September 30, 2025.
  • Stockholders' equity: Total stockholders' equity was $101,068 thousand at June 30, 2026, compared with $64,717 thousand at September 30, 2025.

Enanta's Financial Position and Operating Results for the Quarter Ended June 30, 2026

Enanta Pharmaceuticals, a Delaware-incorporated biopharmaceutical company headquartered in Watertown, Massachusetts, generates revenue through royalties. According to the filing, royalty revenue for the three months ended June 30, 2026 was $14,359 thousand, a decline from $18,314 thousand in the three months ended June 30, 2025. For the nine months ended June 30, 2026, royalty revenue was $50,133 thousand, essentially flat compared with $50,199 thousand in the comparable prior-year period.

Operating expenses for the three months ended June 30, 2026 totaled $31,595 thousand, down from $37,207 thousand a year earlier. Research and development expenses were $22,126 thousand for the quarter, compared with $27,210 thousand in the prior-year quarter. General and administrative expenses were $9,469 thousand versus $9,997 thousand. The resulting loss from operations for the three months ended June 30, 2026 was $17,236 thousand, according to the filing.

The balance sheet as of June 30, 2026 showed cash and cash equivalents of $33,419 thousand and short-term marketable securities of $156,087 thousand. Long-term marketable securities stood at $21,987 thousand, compared with zero at September 30, 2025. The filing also noted that 7,475 thousand shares of common stock were issued in an October 2025 public offering, net of issuance costs of $4,802 thousand, with total proceeds recorded at $69,948 thousand in the stockholders' equity table. The accumulated deficit grew to $449,459 thousand at June 30, 2026 from $404,929 thousand at September 30, 2025. The company is classified as a non-accelerated filer and a smaller reporting company, as indicated on the filing's cover page. The filing trades on NASDAQ:ENTA.

What Was Disclosed

Enanta Pharmaceuticals disclosed unaudited condensed consolidated financial statements for the quarter and nine months ended June 30, 2026, including balance sheet data, statements of operations, stockholders' equity activity, and comprehensive loss figures, as part of its Form 10-Q filed August 12, 2026.